caffeine has been researched along with Diabetes, Gestational in 10 studies
Diabetes, Gestational: Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant (PREGNANCY IN DIABETICS). Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to INSULIN RESISTANCE; GLUCOSE INTOLERANCE; and HYPERGLYCEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compounds other than macronutrients have been shown to influence blood glucose concentrations and insulin sensitivity in people with diabetes, with caffeine being one such substance." | 8.89 | Systematic review of randomised controlled trials of the effects of caffeine or caffeinated drinks on blood glucose concentrations and insulin sensitivity in people with diabetes mellitus. ( White, H; Whitehead, N, 2013) |
| "To determine whether caffeinated-beverage intake and plasma caffeine and paraxanthine are associated with cardiometabolic complications in pregnancy (ie, gestational diabetes [GDM], preeclampsia, and gestational hypertension [GH])." | 8.02 | Assessment of Caffeine Consumption and Maternal Cardiometabolic Pregnancy Complications. ( Gleason, JL; Grantz, KL; Grewal, J; Hinkle, SN; Mumford, SL; Sundaram, R; Yisahak, SF; Zhang, C; Zhao, SK, 2021) |
| "Recent work showing that caffeine impairs glucose tolerance may be of particular concern in pregnancy because of a possible negative effect on fetal outcome." | 5.14 | Acute caffeine ingestion and glucose tolerance in women with or without gestational diabetes mellitus. ( Graham, TE; Robinson, LE; Smith, GN; Spafford, C, 2009) |
| "Compounds other than macronutrients have been shown to influence blood glucose concentrations and insulin sensitivity in people with diabetes, with caffeine being one such substance." | 4.89 | Systematic review of randomised controlled trials of the effects of caffeine or caffeinated drinks on blood glucose concentrations and insulin sensitivity in people with diabetes mellitus. ( White, H; Whitehead, N, 2013) |
| "To determine whether caffeinated-beverage intake and plasma caffeine and paraxanthine are associated with cardiometabolic complications in pregnancy (ie, gestational diabetes [GDM], preeclampsia, and gestational hypertension [GH])." | 4.02 | Assessment of Caffeine Consumption and Maternal Cardiometabolic Pregnancy Complications. ( Gleason, JL; Grantz, KL; Grewal, J; Hinkle, SN; Mumford, SL; Sundaram, R; Yisahak, SF; Zhang, C; Zhao, SK, 2021) |
| "The pregnancy was complicated by maternal gestational diabetes mellitus and pre-eclampsia." | 1.46 | A Newborn Infant With Oxygen Desaturation During Sleep. ( Daftary, A; Deschamp, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hinkle, SN | 2 |
| Gleason, JL | 1 |
| Yisahak, SF | 1 |
| Zhao, SK | 1 |
| Mumford, SL | 1 |
| Sundaram, R | 1 |
| Grewal, J | 1 |
| Grantz, KL | 1 |
| Zhang, C | 1 |
| Chen, LW | 1 |
| Laughon, SK | 1 |
| Catov, JM | 1 |
| Olsen, J | 1 |
| Bech, BH | 1 |
| Simhan, HN | 1 |
| Deschamp, A | 1 |
| Daftary, A | 1 |
| Robinson, LE | 1 |
| Spafford, C | 1 |
| Graham, TE | 1 |
| Smith, GN | 1 |
| Whitehead, N | 1 |
| White, H | 1 |
| Reece, EA | 1 |
| Wisborg, K | 1 |
| Adeney, KL | 1 |
| Williams, MA | 1 |
| Schiff, MA | 1 |
| Qiu, C | 1 |
| Sorensen, TK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of the Administration of Chlorogenic Acid on Glucemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance[NCT02621060] | Phase 2 | 30 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects underwent a 2-h oral glucose tolerance test (2-h OGTT) by consuming 75-g of a dextrose load, and one sample was obtained 120 min after glucose administration. (NCT02621060)
Timeframe: Week 12.
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 9.0 |
| Chlorogenic Acid | 8.5 |
Area under the curve of glucose was obtained using the trapezoidal integration. (NCT02621060)
Timeframe: Week 12.
| Intervention | mmol/l/min (Mean) |
|---|---|
| Placebo | 1187 |
| Chlorogenic Acid | 1145 |
Before and after intervention area under the curve of insulin (NCT02621060)
Timeframe: Week 12.
| Intervention | pmol/L/min (Mean) |
|---|---|
| Placebo | 67,322 |
| Chlorogenic Acid | 72,857 |
The Body Mass index was calculated at baseline and at week 12 with the Quetelet index and the entered values reflect the body mass index at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | kg/m^2 (Mean) |
|---|---|
| Placebo | 32.0 |
| Chlorogenic Acid | 31.4 |
The weight was measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance and the entered values reflect the weight at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | kg (Mean) |
|---|---|
| Placebo | 81.3 |
| Chlorogenic Acid | 80.8 |
The creatinine levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the uric acid levels at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 0.06 |
| Chlorogenic Acid | 0.06 |
The Diastolic blood plessure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 78 |
| Chlorogenic Acid | 74 |
Reflect the fasting glucose level after a 10- to 12-h overnight fast. (NCT02621060)
Timeframe: Week 12.
| Intervention | mmol/L (Median) |
|---|---|
| Placebo | 5.8 |
| Chlorogenic Acid | 5.5 |
After intervention with Stumvoll index (NCT02621060)
Timeframe: Week 12.
| Intervention | Unitless (Mean) |
|---|---|
| Placebo | 1281 |
| Chlorogenic Acid | 1133 |
Before and after intervention by spectrophotometry (NCT02621060)
Timeframe: Week 12.
| Intervention | IU/L (Mean) |
|---|---|
| Placebo | 22.03 |
| Chlorogenic Acid | 17.79 |
Before and after intervention by spectrophotometry (NCT02621060)
Timeframe: Week 12.
| Intervention | IU/L (Mean) |
|---|---|
| Placebo | 25.25 |
| Chlorogenic Acid | 22.64 |
Shows what a person's average blood glucose level was for the 2 to 3 months before the test high-performance. (NCT02621060)
Timeframe: Week 12.
| Intervention | Percentage of A1C (Mean) |
|---|---|
| Placebo | 5.8 |
| Chlorogenic Acid | 5.5 |
The HDL-C levels were evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the HDL-C level at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 1.5 |
| Chlorogenic Acid | 1.8 |
After intervention Matsuda Index (NCT02621060)
Timeframe: Week 12.
| Intervention | Unitless (Mean) |
|---|---|
| Placebo | 2.43 |
| Chlorogenic Acid | 2.30 |
The LDL-C levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the LDL-C levels at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 2.7 |
| Chlorogenic Acid | 1.9 |
The Systolic Blood Pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 118 |
| Chlorogenic Acid | 113 |
The total cholesterol was estimated by standardized techniques at baseline and week 12 and the entered values reflect the total cholesterol level at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 5.3 |
| Chlorogenic Acid | 4.3 |
After intervention. Total insulin secretion was calculated with the Insulinogenic index (Δ ABC insulin / Δ ABC glucose). (NCT02621060)
Timeframe: Week 12.
| Intervention | Unitless (Mean) |
|---|---|
| Placebo | 0.55 |
| Chlorogenic Acid | 0.63 |
The triglycerides were evaluated at baseline and week 12 with enzymatic-colorimetric techniques and the entered values reflect the triglycerides level at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 1.7 |
| Chlorogenic Acid | 1.3 |
The uric acid levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the creatinina levels at week 12. (NCT02621060)
Timeframe: Week 12.
| Intervention | mmol/l (Mean) |
|---|---|
| Placebo | 0.34 |
| Chlorogenic Acid | 0.30 |
The VLDL levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the c-LDL levels at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 0.77 |
| Chlorogenic Acid | 0.61 |
Waist circumference was evaluated at baseline and at week 12 with a flexible tape and the entered values reflects the waist circumference measure at week 12 (NCT02621060)
Timeframe: Week 12.
| Intervention | cm (Mean) |
|---|---|
| Placebo | 102 |
| Chlorogenic Acid | 104 |
1 review available for caffeine and Diabetes, Gestational
| Article | Year |
|---|---|
Systematic review of randomised controlled trials of the effects of caffeine or caffeinated drinks on blood glucose concentrations and insulin sensitivity in people with diabetes mellitus.
Topics: Beverages; Blood Glucose; Caffeine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, | 2013 |
1 trial available for caffeine and Diabetes, Gestational
| Article | Year |
|---|---|
Acute caffeine ingestion and glucose tolerance in women with or without gestational diabetes mellitus.
Topics: Adult; Blood Glucose; C-Peptide; Caffeine; Central Nervous System Stimulants; Cross-Over Studies; Di | 2009 |
8 other studies available for caffeine and Diabetes, Gestational
| Article | Year |
|---|---|
Assessment of Caffeine Consumption and Maternal Cardiometabolic Pregnancy Complications.
Topics: Adult; Beverages; Caffeine; Cardiometabolic Risk Factors; Cohort Studies; Diabetes, Gestational; Fem | 2021 |
Is it caffeine? Coffee consumption and future risk of type 2 diabetes among women with a history of gestational diabetes.
Topics: Caffeine; Coffee; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Pregnancy; Prosp | 2022 |
First trimester coffee and tea intake and risk of gestational diabetes mellitus: a study within a national birth cohort.
Topics: Adult; Caffeine; Coffee; Cohort Studies; Denmark; Diabetes, Gestational; Female; Humans; Infant, New | 2015 |
Coffee and tea consumption in pregnancy not associated with gestational diabetes mellitus.
Topics: Caffeine; Coffee; Diabetes, Gestational; Female; Humans; Male; Pregnancy; Pregnancy Trimester, First | 2015 |
A Newborn Infant With Oxygen Desaturation During Sleep.
Topics: Apgar Score; Caffeine; Central Nervous System Stimulants; Diabetes, Gestational; Female; Gestational | 2017 |
Synopsis of the North American Diabetes in Pregnancy Study Group Conference in Little Rock, Arkansas, May 2003.
Topics: Blood Glucose; Caffeine; Cesarean Section; Congenital Abnormalities; Delivery, Obstetric; Diabetes, | 2004 |
Lifestyle during pregnancy and evidence based information.
Topics: Caffeine; Coffee; Diabetes, Gestational; Female; Humans; Life Style; Pregnancy | 2007 |
Coffee consumption and the risk of gestational diabetes mellitus.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Coffee; Diabetes, Gestational; Dose-Response Rel | 2007 |